IgG Fusion Proteins for Brain Delivery of Biologics Via Blood-Brain Barrier Receptor-Mediated Transport

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Jul 27

PMID 35890374

Authors

Ruben J Boado

Affiliations

Soon will be listed here.

Abstract

The treatment of neurological disorders with large-molecule biotherapeutics requires that the therapeutic drug be transported across the blood-brain barrier (BBB). However, recombinant biotherapeutics, such as neurotrophins, enzymes, decoy receptors, and monoclonal antibodies (MAb), do not cross the BBB. These biotherapeutics can be re-engineered as brain-penetrating bifunctional IgG fusion proteins. These recombinant proteins comprise two domains, the transport domain and the therapeutic domain, respectively. The transport domain is an MAb that acts as a molecular Trojan horse by targeting a BBB-specific endogenous receptor that induces receptor-mediated transcytosis into the brain, such as the human insulin receptor (HIR) or the transferrin receptor (TfR). The therapeutic domain of the IgG fusion protein exerts its pharmacological effect in the brain once across the BBB. A generation of bifunctional IgG fusion proteins has been engineered using genetically engineered MAbs directed to either the BBB HIR or TfR as the transport domain. These IgG fusion proteins were validated in animal models of lysosomal storage disorders; acute brain conditions, such as stroke; or chronic neurodegeneration, such as Parkinson's disease and Alzheimer's disease. Human phase I-III clinical trials were also completed for Hurler MPSI and Hunter MPSII using brain-penetrating IgG-iduronidase and -iduronate-2-sulfatase fusion protein, respectively.

Citing Articles

Treating late-onset Tay Sachs disease: Brain delivery with a dual trojan horse protein.

Osher E, Anis Y, Singer-Shapiro R, Urshanski N, Unger T, Albeck S Mol Ther Methods Clin Dev. 2024; 32(3):101300.

PMID: 39211733 PMC: 11357852. DOI: 10.1016/j.omtm.2024.101300.

The Glycocalyx: The Importance of Sugar Coating the Blood-Brain Barrier.

Dancy C, Heintzelman K, Katt M Int J Mol Sci. 2024; 25(15).

PMID: 39125975 PMC: 11312458. DOI: 10.3390/ijms25158404.

Site-oriented conjugation of poly(2-methacryloyloxyethyl phosphorylcholine) for enhanced brain delivery of antibody.

Ren J, Jepson C, Nealy S, Kuhlmann C, Osuka S, Azolibe S Front Cell Dev Biol. 2023; 11:1214118.

PMID: 37920826 PMC: 10618420. DOI: 10.3389/fcell.2023.1214118.

Neurodegenerative Proteinopathies Induced by Environmental Pollutants: Heat Shock Proteins and Proteasome as Promising Therapeutic Tools.

Moyano P, Sola E, Naval M, Guerra-Menendez L, de la Cabeza Fernandez M, Del Pino J Pharmaceutics. 2023; 15(8).

PMID: 37631262 PMC: 10458078. DOI: 10.3390/pharmaceutics15082048.

Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier.

Tien J, Leonoudakis D, Petrova R, Trinh V, Taura T, Sengupta D MAbs. 2023; 15(1):2229098.

PMID: 37381177 PMC: 10312019. DOI: 10.1080/19420862.2023.2229098.

References

Quintern L, Schuchman E, Levran O, Suchi M, Ferlinz K, Reinke H . Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts. EMBO J. 1989; 8(9):2469-73. PMC: 401234. DOI: 10.1002/j.1460-2075.1989.tb08382.x. View

Sumbria R, Hui E, Lu J, Boado R, Pardridge W . Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol Pharm. 2013; 10(9):3507-13. DOI: 10.1021/mp400348n. View

Duffy K, Pardridge W, Rosenfeld R . Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 1988; 37(2):136-40. DOI: 10.1016/s0026-0495(98)90007-5. View

Brady R, Schiffmann R . Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol. 2004; 3(12):752-6. DOI: 10.1016/S1474-4422(04)00938-X. View

Couch J, Yu Y, Zhang Y, Tarrant J, Fuji R, Meilandt W . Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013; 5(183):183ra57, 1-12. DOI: 10.1126/scitranslmed.3005338. View

Lapchak P, Miller P, Collins F, Jiao S . Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience. 1997; 78(1):61-72. DOI: 10.1016/s0306-4522(97)83045-x. View

Magnani P, Paganelli G, Songini C, Samuel A, Sudati F, Siccardi A . Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br J Cancer. 1996; 74(5):825-31. PMC: 2074693. DOI: 10.1038/bjc.1996.443. View

Boado R, Lu J, Hui E, Pardridge W . IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng. 2009; 105(3):627-35. PMC: 2838425. DOI: 10.1002/bit.22576. View

Zhou Q, Hui E, Lu J, Boado R, Pardridge W . Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. Brain Res. 2011; 1382:315-20. PMC: 3057388. DOI: 10.1016/j.brainres.2011.01.061. View

10.

Hendrickson W, Pahler A, Smith J, SATOW Y, Merritt E, Phizackerley R . Crystal structure of core streptavidin determined from multiwavelength anomalous diffraction of synchrotron radiation. Proc Natl Acad Sci U S A. 1989; 86(7):2190-4. PMC: 286877. DOI: 10.1073/pnas.86.7.2190. View

11.

Knoblach S, Fan L, Faden A . Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol. 1999; 95(1-2):115-25. DOI: 10.1016/s0165-5728(98)00273-2. View

12.

Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P . Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014; 81(1):49-60. DOI: 10.1016/j.neuron.2013.10.061. View

13.

Boado R, Zhou Q, Lu J, Hui E, Pardridge W . Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm. 2009; 7(1):237-44. PMC: 2858389. DOI: 10.1021/mp900235k. View

14.

Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M . Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007; 7(1):35-41. DOI: 10.1016/j.autrev.2007.03.003. View

15.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

16.

Boado R, Zhang Y, Zhang Y, Xia C, Wang Y, Pardridge W . Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem. 2008; 19(3):731-9. DOI: 10.1021/bc7004076. View

17.

Ng P, Dela Cruz J, Sorour D, Stinebaugh J, Shin S, Shin D . An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A. 2002; 99(16):10706-11. PMC: 125019. DOI: 10.1073/pnas.162362999. View

18.

Cheng S, Smith A . Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther. 2003; 10(16):1275-81. DOI: 10.1038/sj.gt.3302092. View

19.

Pardridge W, Boado R . Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 2012; 503:269-92. DOI: 10.1016/B978-0-12-396962-0.00011-2. View

20.

Boado R, Pardridge W . Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. Mol Pharm. 2017; 14(4):1271-1277. DOI: 10.1021/acs.molpharmaceut.6b01166. View